Pharming Group
PHAR
3 hedge funds and large institutions have $325K invested in Pharming Group in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
1,179% more capital inflows, than outflows
Capital inflows: $54.3K | Capital outflows: $4.25K
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
0% more funds holding
Funds holding: 3 → 3 (0)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cowen Prime Advisors
New York
|
+$54.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.13K |
| 2 |
Morgan Stanley
New York
|
-$1.12K |
PHAR Hedge Fund Activity: Q4 2022 in Review
3 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q4 2022, worth a combined $325K — up 33% from $245K a quarter earlier.
Fund positioning in PHAR was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Cowen Prime Advisors, adding an estimated $54.3K. The largest seller was UBS Group, cutting an estimated $3.13K.
- 3 institutional investors held Pharming Group (PHAR) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $325K of Pharming Group stock for Q4 2022, up 33% quarter-over-quarter.
- 0 funds opened new Pharming Group positions in Q4 2022 and 0 closed out.
- The largest Pharming Group buyer in Q4 2022 was Cowen Prime Advisors, an estimated $54.3K added.
- The largest Pharming Group seller in Q4 2022 was UBS Group, an estimated $3.13K sold.
Based on aggregated 13F filings for Q4 2022.